Translational and Clinical Pharmacology

Translational and Clinical Pharmacology is the quarterly open-access journal of the Korean Society for Clinical Pharmacology and Therapeutics, published in Busan since 2014, and it carries a 2025 Journal Impact Factor of 2.4.《转化与临床药理学》是韩国临床药理学与治疗学学会的季刊，全刊开放获取，2014 年起以现名在釜山出版，2025 年期刊影响因子为 2.4。

Scope

• Its aims page presents an interdisciplinary journal given to spreading knowledge across every branch of translational and clinical pharmacology, from laboratory measurement to prescribing at the bedside.宗旨页把本刊定位为跨学科刊物，致力于传播转化药理学与临床药理学各分支的知识，从实验室测量一直延伸到床旁处方。
• Pharmacokinetics heads the list of categories, taking in absorption and distribution as well as metabolism and excretion in healthy volunteers, in patients and in groups whose physiology alters exposure.药代动力学列在栏目清单首位，涵盖吸收与分布，也涵盖代谢和排泄，对象包括健康志愿者、患者以及生理状态改变药物暴露的人群。
• Drug metabolism and disposition follow, with enzyme and transporter work, mass-balance studies of radiolabelled doses and the prediction of human clearance from in vitro data in liver microsomes.药物代谢与处置紧随其后，涉及酶与转运体研究，也涉及放射性标记剂量的物料平衡试验，以及从人肝微粒体体外数据推算人体清除率。
• Pharmacodynamics covers biomarkers and target engagement, together with the shape of the concentration-effect relationship, and it favours endpoints that can travel from a first-in-human trial into routine prescribing.药效学覆盖生物标志物与靶点结合，也覆盖浓度效应关系的形态，并偏重那些能从首次人体试验走进常规处方的终点指标。
• Clinical trials and design issues attract first-in-human protocols, adaptive dose finding, ethnic bridging studies and the methodological arguments that decide whether a trial answers its own clinical question.临床试验与设计问题接收首次人体试验方案，也接收适应性剂量探索与种族桥接研究，还包括决定试验能否回答其临床问题的设计学讨论。
• Pharmacometrics brings population modelling, exposure-response analysis and target concentration intervention, the last of which appears in a paper on aminoglycoside dosing in the current issue of the journal.定量药理学带来群体建模与暴露反应分析，也带来目标浓度干预，本刊现行一期中一篇氨基糖苷类给药论文正属此列。
• Pharmacogenomics asks how inherited variation in drug-metabolising enzymes and transporters changes the dose a patient needs, while pharmacometabolomics reads the metabolic signature that a drug leaves behind in plasma or urine.药物基因组学追问药物代谢酶与转运体的遗传变异如何改变患者所需剂量，药物代谢组学则解读药物在血浆或尿液中留下的代谢特征。
• Pharmacoepidemiology draws on claims databases, registries and electronic health records to describe how medicines perform once they leave the controlled conditions of a randomised trial, and which harms appear only at population scale.药物流行病学借助医保数据库与登记系统，也借助电子病历，描述药物离开随机试验的受控条件之后的实际表现，以及哪些危害只在人群尺度上显形。
• Pharmacovigilance and postmarketing surveillance reports sit alongside it, covering spontaneous reporting, adverse event signals, causality assessment and the safety questions that only wide exposure after approval can answer.药物警戒与上市后监测报告与之并列，涉及自发报告与不良事件信号，也涉及因果判断，以及只有获批后大范围用药才能回答的安全性疑问。
• Pharmaceutical medicine and regulatory science complete the clinical side, addressing development strategy, the wording of product labels and the kind of evidence a regulator accepts when it grants approval.药物医学与监管科学补足临床一侧，讨论开发策略与产品说明书表述，也讨论监管机构在批准时接受何种证据。
• Human pharmacology keeps a place of its own, with studies in healthy volunteers, phenotyping of metabolic capacity and observation of a drug candidate at its first exposure to people.人体药理学自有位置，收录健康志愿者研究，也收录代谢能力表型分析，以及候选药物首次进入人体时的药理观察。
• Animal work is admitted where it characterises a compound or supports a clinical question, so preclinical pharmacology has an entry without claiming a section of its own.动物实验在能刻画化合物性质或支撑临床问题时获准刊发，临床前药理因此有入口，却不单独占据一个栏目。
• Bioequivalence reports keep the original article format with a shortened discussion, a category shaped by the scale of generic-product bridging carried out across the region each year.生物等效性报告沿用原创论文格式并压缩讨论部分，这一栏目的规模与区域内仿制药桥接研究的体量相称。
• Each category is open to work done in Korea and abroad, and the aims page asks only that a submission speak to drug action in humans or to the path leading there.各栏目对韩国境内与境外的研究一并开放，宗旨页只要求来稿讨论药物在人体的作用，或讨论通向这一结论的路径。

History

• The title began in 1993 as the Journal of Korean Society for Clinical Pharmacology and Therapeutics, whose first volume carried two issues under the society's imprint and the print ISSN 1225-5467.本刊 1993 年以《韩国临床药理学与治疗学学会杂志》之名创刊，第 1 卷在学会自印下出两期，印刷版 ISSN 为 1225-5467。
• Volume numbering has never restarted, so the relaunch of 2014 opened at volume 22 and the issues of 2026 sit in volume 34, with one volume completed each calendar year since the first.卷号从未重新起算，2014 年改版时直接进入第 22 卷，2026 年的各期属于第 34 卷，自首卷起每个日历年完成一卷。
• The seventh volume came out in 1999 as a single combined number, a detail the archive still prints beside the regular two-issue years that surround it on either side.第 7 卷在 1999 年以合刊形式出版，这一细节在档案列表中仍与前后常规两期的年份并列可见。
• A retitling took effect with volume 22 in 2014, when the journal took its present name and the pair of print and electronic ISSNs 2289-0882 and 2383-5427 that identify it today.2014 年第 22 卷起启用现名，同时换用今天标识本刊的印刷版与电子版 ISSN，即 2289-0882 与 2383-5427。
• Two issues a year gave way to four with volume 24 in 2016, and every volume since has carried numbers one through four, so the quarterly schedule now in force dates from that year.每年两期的安排到 2016 年第 24 卷改为四期，此后每卷都编有一至四号，现行季刊节奏即从那年算起。
• The current issue is dated September 2026 and carries volume 34, number 3, while 2025 closed as volume 33 with all four numbers, the last of them in December, published on time.现行一期标注 2026 年 9 月，为第 34 卷第 3 期，2025 年以第 33 卷收官，四期全部出齐，最后一期在 12 月如期面世。
• The National Library of Medicine record still prints Semiannual as the frequency, a description the published volumes left behind when the fourth issue of each year began to appear.美国国家医学图书馆的记录仍把刊期写作半年刊，这一描述在每年第四期开始出现之后即已过时。
• PubMed began indexing the journal with volume 26, number 1, in March 2018, and the full text of every article accepted since then is deposited in PubMed Central without delay.PubMed 自 2018 年 3 月的第 26 卷第 1 期起收录，此后每篇录用稿的全文都即时存入 PubMed Central。
• No subscription stands between a reader and the text, and Clarivate counts the gold open access share of the content at 100 percent, a figure the society treats as policy.读者与正文之间没有订阅门槛，Clarivate 统计的金色开放获取比例为 100%，学会把这一比例当成既定方针。
• Digital object identifiers run under the prefix 10.12793, and recent articles carry e-locators such as 2026.34.e13 instead of page ranges, so an accepted paper can appear before its issue closes.数字对象标识符使用 10.12793 前缀，近期文章以 2026.34.e13 这类电子编号代替页码，录用稿得以在整期定稿前先行上线。
• Indexing runs through Emerging Sources Citation Index, PubMed, PubMed Central, Scopus, EMBASE, KoreaMed, the Korean Citation Index and KoMCI, the full set that the aims page prints for prospective authors.收录渠道包括 Emerging Sources Citation Index 与 PubMed，也包括 PubMed Central 与 Scopus，另有 EMBASE、KoreaMed、韩国引文索引与 KoMCI，宗旨页把这份名单原样列给投稿人。
• Clarivate started issuing the Journal Impact Factor to Emerging Sources titles in 2023, and the record for this journal opens in that year at 1.1, its first such number.Clarivate 从 2023 年起向 Emerging Sources 收录刊发放影响因子，本刊的记录即从这一年的 1.1 开始，这也是它的第一个此类数值。
• The indicator reached 1.5 in 2024 and 2.4 in 2025, alongside a five-year value of 2.0, a Journal Citation Indicator of 0.41 and a third-quartile place at 215 of 356 journals in pharmacology and pharmacy.该指标 2024 年为 1.5，2025 年升至 2.4，五年影响因子为 2.0，期刊引文指标为 0.41，在药理学与药学类 356 种刊物中排第 215 位，属第三四分位。
• Output is small, at about sixteen papers a year, and the 2025 file shows 405 citations in total, a cited half-life of 5.8 years and a percentile of 39.7 for the title.年发文量不大，约 16 篇，2025 年的记录显示总被引 405 次，被引半衰期为 5.8 年，百分位为 39.7。

Editors

• Jae-Yong Chung, a clinical pharmacologist at Seoul National University, holds the post of Editor-in-Chief and signs the final decision on every manuscript, whether it is accepted or declined.首尔大学的临床药理学家 Jae-Yong Chung 担任主编，每篇稿件无论录用还是退稿，终裁都由他签署。
• The aims page says review articles usually arrive by invitation, while the author instructions now welcome unsolicited reviews and promise them the same external peer review as other work.宗旨页说综述通常以约稿方式组稿，作者须知则明确欢迎自投综述，并承诺与其它稿件一样送外审。
• Five associate editors carry the flow of manuscripts, among them Kyun-Seop Bae and Hyeong-Seok Lim at the University of Ulsan and Howard Lee at Seoul National University.五位副编辑分担稿件流转，其中有蔚山大学的 Kyun-Seop Bae 与 Hyeong-Seok Lim，也有首尔大学的 Howard Lee。
• Hanlim Moon works at Connect Clinical Sciences and Sung-Vin Yim at Kyunghee University, which puts two of the five associate editors outside the country's large teaching hospitals.Hanlim Moon 任职于 Connect Clinical Sciences，Sung-Vin Yim 任职于庆熙大学，五位副编辑中有两位不在国内大型教学医院。
• Jung Sang Lee is recorded as Founding Editor, and Sang-Goo Shin of Seoul National University carries the title Editor Emeritus, keeping the society's first generation on the masthead.Jung Sang Lee 被列为创刊编辑，首尔大学的 Sang-Goo Shin 拥有荣休编辑称号，两项头衔把学会第一代人留在刊头。
• Nineteen names fill the editorial board, drawn mostly from Korean medical and pharmacy schools such as the Catholic University of Korea, Chosun University, Ewha Womans University and Jeonbuk National University.编委会由 19 人组成，多数来自韩国医学院与药学院，例如韩国天主教大学、朝鲜大学、梨花女子大学与全北大学。
• Chungnam National University supplies three board members and Kyungpook National University two, while the rest are spread across Kyunghee University, Inje University, Hongik University and Samsung Medical Center.忠南大学提供三位编委，庆北大学两位，其余分散在庆熙大学、仁荷大学、弘益大学与三星医疗中心。
• The board reaches abroad for Nick Holford at the University of Auckland and Yuji Kumagai at Kitasato University in Japan, both known for modelling and early-phase clinical work.编委也向海外延伸，奥克兰大学的 Nick Holford 与日本北里大学的 Yuji Kumagai 在列，两人都以建模与早期临床研究见长。
• Industry and consultancy seats are held by Eunkyoung Kim of Bristol-Myers-Squibb, Wonsik Lee of Idience, Susie Kim of IntegrityWrite and Yaning Wang of Rui Ning Kang Pharma.产业与咨询界席位由百时美施贵宝的 Eunkyoung Kim、Idience 的 Wonsik Lee、IntegrityWrite 的 Susie Kim 与 Rui Ning Kang Pharma 的 Yaning Wang 占据。
• Every manuscript goes to at least two expert reviewers in double-blind form, and authors usually receive an editorial report within a month of a complete submission reaching the office.每篇稿件至少送两位专家以双盲方式评审，完整来稿抵达编辑部后通常一个月内收到编辑报告。
• A rejection may be appealed in writing within two weeks of the decision letter, and invited papers can be assessed internally by editors as well as externally.退稿可在决定函发出两周内书面申诉，约稿既可由编辑内部评估，也可送外部评审。
• Original articles run to 5,000 words and 30 references, reviews and tutorials to 6,500 and 60, perspectives to 4,000 and 50, and case reports to 5,000 and 30, all excluding the abstract, as the author instructions put it.原创论文上限 5000 词与 30 条参考文献，综述与教程为 6500 词与 60 条，观点文章为 4000 词与 50 条，病例报告为 5000 词与 30 条，字数一律不计摘要。
• Manuscripts arrive through Editorial Manager as a Word file in AMA style, with an unstructured abstract under 250 words, three to five MeSH keywords and a CRediT statement.稿件经 Editorial Manager 以 Word 文件递交，行文依 AMA 格式，附 250 词以内的非结构式摘要、3 至 5 个 MeSH 关键词与 CRediT 贡献声明。
• Use of artificial intelligence must be declared with the tool, model and version, and preprints are considered case by case where the author still holds the copyright.使用人工智能工具须申报工具名称、模型与版本，作者保留版权的预印本可按个案受理。